A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria. (REVISIT)
A Phase 3 comparative study to determine the efficacy, safety and tolerability of
Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) versus Meropenem (MER) ± Colistin (COL)
for the treatment of serious infections due to Gram negative bacteria.
A Phase 3 Prospective, Randomized, Multicenter, Open Label, Central Assessor Blinded,
Parallel Group, Comparative Study To Determine The Efficacy, Safety And Tolerability Of
Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem±Colistin (MER±COL) For
The Treatment Of Serious Infections Due To Gram Negative Bacteria, Including Metallo Β
Lactamase (MBL) - Producing Multidrug Resistant Pathogens, For Which There Are Limited Or No
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.